Evotec
Anne Stinn is an accomplished Postdoctoral Research Scientist at Evotec, leading the Protein Production Unit within the Biophysics Department since April 2019. Responsibilities include designing, expressing, and purifying recombinant proteins, with a focus on isotopically labeled proteins for bio NMR applications, while ensuring quality management and project execution in collaboration with various research teams. Prior experience includes roles as a Postdoctoral Research Associate at the Max Planck Institute for Infection Biology and a PhD student with a focus on Protein Biochemistry and Structural Biology. Earlier positions include internships and research assistant roles at UCL Cancer Institute and Justus Liebig University Giessen, where Anne gained extensive skills in molecular biology, protein analysis, and research project management. Educational qualifications comprise a PhD in Biochemistry and Structural Biology from Humboldt-Universität zu Berlin, an MS in Microbiology and Immunology, and a BS in Biology, both from Justus Liebig University Giessen.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.